Drug Profile

Research programme: Mucosal associated invariant T cell therapies - Pluri

Latest Information Update: 18 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 Apr 2025 Pluri has two granted patents for mucosal associated invariant T cell therapies in USA and Israel
29 Oct 2024 Pluri and Bar-Ilan University Research and Development Company agree to co-develop Mucosal associated invariant T cell therapies in Israel for Solid tumours
29 Oct 2024 Early research in Solid tumours in Israel (Parenteral) prior to October 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com